阿昔替尼联合DCCIK细胞治疗晚期难治性肾癌的疗效

doi:10.3760/cma.j.issn.1673-422X.2016.01.019

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (10): 797-799.doi: 10.3760/cma.j.issn.1673-422X.2016.01.019

阿昔替尼联合DCCIK细胞治疗晚期难治性肾癌的疗效

许振胜,符芳姿,王美清,李建旺,张玮芳

570208 海南省海口市人民医院肿瘤化疗科

出版日期:2016-10-08 发布日期:2016-09-07
通讯作者: 符芳姿 E-mail:22247316@qq.com

Online:2016-10-08 Published:2016-09-07

摘要/Abstract

许振胜,符芳姿,王美清,李建旺,张玮芳. 阿昔替尼联合DCCIK细胞治疗晚期难治性肾癌的疗效[J]. 国际肿瘤学杂志, 2016, 43(10): 797-799.

［1］ Algaba F. Rereading the renal cell tumors［J］. Int J Surg Pathol, 2010, 18(3): 9497. DOI: 10.1177/1066896910370468. ［2］ Hase S, Weinitschke K, Fischer K, et al. Monitoring perioperative immune suppression in renal cancer patients［J］. Oncol Rep, 2011, 25(5): 14551464. DOI: 10.3892/or.2011.1199. ［3］王欢, 周芳坚, 王其京, 等. 负载自体肿瘤细胞裂解物的DC疫苗联合CIK治疗晚期肾癌的临床观察附10例报告［J］. 癌症, 2006, 25(5): 625630. DOI: 10.3321/j.issn:1000467X.2006.05.021. ［4］ GrossGoupil M, Massard C, Ravaud A, Targeted therapies in metastatic renal cell carcinoma: overview of the past year［J］. Curr Urol Rep, 2012, 13(1): 1623. DOI: 10.1007/s119340110232y. ［5］ Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomized trials［J］. BJU Int, 2011, 108(10): 15561663. DOI: 10.1111/j.1464410X.2011.10629.x. ［6］ Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma［J］. Drugs R D, 2011, 11(2): 113126. DOI: 10.2165/1159124000000000000000. ［7］ Rini BI, de La Motte Rouge T, Harzstark AL, et al. Fiveyear survival in patients with cytokinerefractory metastatic renal cell carcinoma treated with axitinib［J］. Clin Genitourin Cancer, 2013, 11(2): 107114. DOI: 10.1016/j.clgc.2012.12.004. ［8］ Weikert S, Kempkensteffen C, Busch J, et al. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors［J］. World J Urol, 2013, 31(4): 805809. DOI: 10.1007/s0034501106761. ［9］ Snover DC. Update on the serrated pathway to colorectal carcinoma［J］. Hum Pathol, 2011, 42(1): 110. DOI: 10.1016/j.humpath.2010.06.002. ［10］ Wehner R, Dietze K, Bachmann M, et al. The bidirectional crosstalk between human dendritic cells and natural killer cells［J］. J Innate Immun, 2011, 3(3): 258263. DOI: 10.1159/000323923. ［11］Kim JS, Chung IS, Lim SH, et al. Preclinical and clinical studies on cytokineinduced killer cells for the treatment of renal cell carcinoma［J］. Arch Pharm Res, 2014, 37(5): 559566. DOI: 10.1007/s122720140381x. ［12］李建旺, 黄春珍, 李建华, 等. 自体CIK细胞及DC细胞联合索拉非尼治疗转移性肾癌的疗效与安全性［J］. 山东医药, 2012, 52(1): 79. DOI: 10.3969/j.issn.1002266X.2012.01.004. ［13］杨茂, 郭志, 司同国, 等. 动脉栓塞联合CIK细胞对中晚期肾癌患者免疫功能的影响［J］. 临床放射学杂志, 2011, 30(3): 398401. ［14］李霞, 徐文漭, 崔静, 等. CIK细胞治疗局限性肾癌的疗效［J］. 肿瘤防治研究, 2011, 38(8): 950953. DOI: 10.3971/j.issn.10008578.2011.08.025. ［15］Huang Y, Wang Y, Li Y, et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2［J］. J Cancer Res Clin Oncol, 2011, 137(5): 829837. DOI: 10.1007/s0043201009442. ［16］Romero AI, Chaput N, PoirierColame V, et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL15R and NKG2D triggering［J］. Cancer Res, 2014, 74(1): 6880. DOI: 10.1158/00085472.CAN131186. ［17］Morelli MB, Amantini C, Santoni M, et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells［J］. Oncotarget, 2015, 6(34): 3624536259. DOI: 10.18632/oncotarget.5768.

阿昔替尼联合DCCIK细胞治疗晚期难治性肾癌的疗效

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价